OTC · NVIVQ
InVivo Therapeutics Holdings Corporation
Healthcare · Biotechnology
$0.37
Up+$0.04 (+12.12%)
Updated Aug 17, 2026, 12:25 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.15M
- P/E ratio
- —
- Dividend yield
- —
- 52-week range
- — – —
- Volume
- 824
- Avg. volume
- 7.37K
Price performance
NVIVQ price history
1M range · 0 trading sessions · Daily adjusted prices
NVIVQ does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest NVIVQ news
The latest Smart Investors Daily articles mentioning NVIVQ.
Stock researchCompany · Overview
NVIVQ research
Overview
Company profile and research snapshot.
Company profile
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- —
- Implied upside
- —
- Analysts
- 9
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
